ustekinumab subcutaneous — Medica

Initial criteria

• age > 18 years
• According to the prescriber, the patient will receive a single induction dose with ustekinumab intravenous within 2 months of initiating therapy with ustekinumab subcutaneous
• The medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on the requested drug for at least 6 months
• Patient meets at least ONE of the following: (a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples include fecal calprotectin, C-reactive protein, endoscopic assessment, or reduced corticosteroid dose) OR (b) Compared with baseline, patient experienced improvement in at least one symptom such as decreased pain, fatigue, stool frequency, and/or decreased rectal bleeding

Approval duration

Initial: 6 months; Reauthorization: 1 year